Clinical trial
A Dose-Escalating Study of Ro 31-8959 ( HIV Protease Inhibitor ) in Patients With HIV Disease.
NCT00002111 is registered in ClinicalTrials.gov with Stanford University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Dose-Escalating Study of Ro 31-8959 ( HIV Protease Inhibitor ) in Patients With HIV Disease.
- Lead sponsor
- Stanford University
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- Not reported
- Completion date
- Not reported
- Enrollment
- 32
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.